These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330 [TBL] [Abstract][Full Text] [Related]
5. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis. Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144 [TBL] [Abstract][Full Text] [Related]
6. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis. Divita KM; Khatik GL Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802 [TBL] [Abstract][Full Text] [Related]
7. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697 [TBL] [Abstract][Full Text] [Related]
8. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. Andries K; Villellas C; Coeck N; Thys K; Gevers T; Vranckx L; Lounis N; de Jong BC; Koul A PLoS One; 2014; 9(7):e102135. PubMed ID: 25010492 [TBL] [Abstract][Full Text] [Related]
9. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589 [TBL] [Abstract][Full Text] [Related]
10. Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of Wang Z; Soni V; Marriner G; Kaneko T; Boshoff HIM; Barry CE; Rhee KY Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19646-19651. PubMed ID: 31501323 [TBL] [Abstract][Full Text] [Related]
11. Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for Sivaramakrishnan G; Subramanyam B; Kumar MP; Golla R; Tripathy SP; Mondal R Int J Mycobacteriol; 2019; 8(4):329-332. PubMed ID: 31793501 [TBL] [Abstract][Full Text] [Related]
12. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684 [TBL] [Abstract][Full Text] [Related]
13. An amiloride derivative is active against the F Hards K; Cheung CY; Waller N; Adolph C; Keighley L; Tee ZS; Harold LK; Menorca A; Bujaroski RS; Buckley BJ; Tyndall JDA; McNeil MB; Rhee KY; Opel-Reading HK; Krause K; Preiss L; Langer JD; Meier T; Hasenoehrl EJ; Berney M; Kelso MJ; Cook GM Commun Biol; 2022 Feb; 5(1):166. PubMed ID: 35210534 [TBL] [Abstract][Full Text] [Related]
14. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]
15. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. Karmakar M; Rodrigues CHM; Holt KE; Dunstan SJ; Denholm J; Ascher DB PLoS One; 2019; 14(5):e0217169. PubMed ID: 31141524 [TBL] [Abstract][Full Text] [Related]
16. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Worley MV; Estrada SJ Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970 [TBL] [Abstract][Full Text] [Related]
17. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. Dupont C; Viljoen A; Thomas S; Roquet-Banères F; Herrmann JL; Pethe K; Kremer L Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807917 [TBL] [Abstract][Full Text] [Related]
18. Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline. Krah A; Ragunathan P; Bond PJ; Grüber G Biochem Biophys Res Commun; 2024 Jan; 690():149249. PubMed ID: 38000294 [TBL] [Abstract][Full Text] [Related]
19. TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug's Uncoupler Activity. Sarathy JP; Ragunathan P; Cooper CB; Upton AM; Grüber G; Dick T Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712198 [TBL] [Abstract][Full Text] [Related]
20. Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis. Mackenzie JS; Lamprecht DA; Asmal R; Adamson JH; Borah K; Beste DJV; Lee BS; Pethe K; Rousseau S; Krieger I; Sacchettini JC; Glasgow JN; Steyn AJC Nat Commun; 2020 Nov; 11(1):6092. PubMed ID: 33257709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]